485 reports of this reaction
3.1% of all CEFDINIR reports
#2 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #2 most commonly reported adverse reaction for CEFDINIR, manufactured by American Health Packaging. There are 485 FDA adverse event reports linking CEFDINIR to CHRONIC KIDNEY DISEASE. This represents approximately 3.1% of all 15,428 adverse event reports for this drug.
Patients taking CEFDINIR who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is moderately reported among CEFDINIR users, representing a notable but not dominant share of adverse events.
In addition to chronic kidney disease, the following adverse reactions have been reported for CEFDINIR:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 485 FDA reports for CEFDINIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 3.1% of all adverse event reports for CEFDINIR, making it one of the most commonly reported side effect.
If you experience chronic kidney disease while taking CEFDINIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.